Valentina L. Greto

Valentina L. Greto

Auto-generated profile, based on publicly available information

Valentina L. Greto

Translational Gastroenterology Unit and NIHR Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Metabolism
Verified
Journal Article
Closed access
APAndrea Palermo
Andrea Palermo
Dario TuccinardiDario Tuccinardi
Dario Tuccinardi
LDLuca D'Onofrio
Luca D'Onofrio
Mikiko WatanabeMikiko Watanabe
Mikiko Watanabe
DMDaria Maggi
Daria Maggi
SMSilvia Manfrini
Silvia Manfrini

3 May 2021 in International Journal of Obesity
Verified
Journal Article
Open access
PDF file
VGValentina L. Greto
Valentina L. Greto
ACAna Cvetko
Ana Cvetko
TŠTamara Štambuk
Tamara Štambuk
NDNiall J. Dempster
Niall J. Dempster
DKDomagoj Kifer
Domagoj Kifer
Gordan LaucGordan Lauc
Gordan Lauc
Background: Obesity, a major global health problem, is associated with increased cardiometabolic morbidity and mortality. Protein glycosylation is a frequent posttranslational modification, highly responsive to inflammation and ageing. The prospect of biological age reduction, by changing glycosylation patterns through metabolic intervention, opens many possibilities. We have investigated whether weight loss interventions affect inflammation- and ageing-associated IgG glycosylation changes, in a longitudinal cohort of bariatric surgery patients. To support potential findings, BMI-related glycosylation changes were monitored in a longitudinal twins cohort. Methods: IgG N-glycans were chromatographically profiled in 37 obese patients, subjected to low-calorie diet, followed by bariatric surgery, across multiple timepoints. Similarly, plasma-derived IgG N-glycan traits were longitudinally monitored in 1680 participants from the TwinsUK cohort. Results: Low-calorie diet induced a marked decrease in the levels of IgG N-glycans with bisecting GlcNAc, whose higher levels are usually associated with ageing and inflammatory conditions. Bariatric surgery resulted in extensive alterations of the IgG N-glycome that accompanied progressive weight loss during 1-year follow-up. We observed a significant increase in digalactosylated and sialylated glycans, and a substantial decrease in agalactosylated and core fucosylated IgG N-glycans (adjusted p value range 7.38 × 10−04–3.94 × 10−02). This IgG N-glycan profile is known to be associated with a younger biological age and reflects an enhanced anti-inflammatory IgG potential. Loss of BMI over a 20 year period in the TwinsUK cohort validated a weight loss-associated agalactosylation decrease (adjusted p value 1.79 × 10−02) and an increase in digalactosylation (adjusted p value 5.85 × 10−06). Conclusions: Altogether, these findings highlight that weight loss substantially affects IgG N-glycosylation, resulting in reduced glycan and biological age.

1 March 2018 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
NNNicola Napoli
Nicola Napoli
RSRocky Strollo
Rocky Strollo
Giuseppe DefeudisGiuseppe Defeudis
Giuseppe Defeudis
GLGaetano Leto
Gaetano Leto
CMChiara Moretti
Chiara Moretti
RBRaffaella Buzzetti
Raffaella Buzzetti
Purpose: Bone formation is impaired in both type 1 diabetes and type 2 diabetes (T2D), whereas sclerostin, an antagonist of bone formation, is increased in T2D only. No data are available on latent autoimmune diabetes in adults (LADA), an autoimmune type of diabetes that may clinically resemble T2D at diagnosis. We evaluated serum sclerostin and bone turnover markers in LADA compared with those in T2D and whether metabolic syndrome (MetS) affects sclerostin in T2D or LADA. Methods: This cross-sectional study included 98 patients with T2D and 89 with LADA from the Action LADA and Non Insulin Requiring Autoimmune Diabetes cohorts. Patients were further divided according to MetS status. Nondiabetic participants (n = 53) were used as controls. Serum sclerostin, bone formation (pro-collagen type 1 N-terminal propeptide [P1NP]), and bone resorption (C-terminal telopeptide of type I collagen [CTX]) were analyzed. Results: Patients with T2D had higher sclerostin than did those with LADA [P = 0.0008, adjusted for sex and body mass index (BMI)], even when analysis was restricted to patients with MetS (adjusted P = 0.03). Analysis of T2D and LADA groups separately showed that sclerostin was similar between those with and those without MetS. However, a positive trend between sclerostin and number of MetS features was seen with T2D (P for trend = 0.001) but not with LADA. Patients with T2D or LADA had lower CTX than did controls (P = 0.0003) and did not have significantly reduced P1NP. Sclerostin was unrelated to age or hemoglobin A1c but was correlated with BMI (ρ = 0.29; P = 0.0001), high-density lipoprotein (ρ = −0.23; P = 0.003), triglycerides (ρ = 0.19; P = 0.002), and time since diagnosis (ρ = 0.32; P < 0.0001). Conclusions: Patients with LADA presented lower bone resorption than did controls, similar to patients with T2D. Sclerostin is increased in T2D but not in LADA, suggesting possible roles on bone metabolism in T2D only.

23 January 2024 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Closed access
TŠTamara Štambuk
Tamara Štambuk
DKDomagoj Kifer
Domagoj Kifer
VGValentina L. Greto
Valentina L. Greto
NDNiall J. Dempster
Niall J. Dempster
ACAna Cvetko
Ana Cvetko
CACarolina V. Arancibia-Cárcamo
Carolina V. Arancibia-Cárcamo

29 April 2020 in medRxiv
Verified
Preprint
Open access
PDF file
VGValentina L Greto
Valentina L Greto
ACAna Cvetko
Ana Cvetko
TŠTamara Štambuk
Tamara Štambuk
NDNiall J Dempster
Niall J Dempster
DKDomagoj Kifer
Domagoj Kifer
Gordan LaucGordan Lauc
Gordan Lauc
Background: Obesity is a major global health problem, and is associated with increased cardiometabolic morbidity and mortality. Protein glycosylation is a frequent postranslational modification, highly responsive to numerous pathophysiological conditions and ageing. The prospect of biological age reduction, by reverting glycosylation changes through metabolic intervention, opens many possibilities. We have investigated whether weight loss interventions affect inflammation- and ageing-associated IgG glycosylation changes, in a longitudinal cohort of bariatric surgery patients. To support potential findings, BMI-related glycosylation changes were monitored in a longitudinal twins cohort. Methods: IgG N-glycans were chromatographically profiled in 37 obese patients, subjected to low-calorie diet, followed by bariatric surgery, across multiple timepoints. Similarly, plasma-derived IgG N-glycan traits were longitudinally monitored in 1,680 participants from the TwinsUK cohort. Results: Low-calorie diet induced a marked decrease in the levels of IgG N-glycans with bisecting GlcNAc, whose higher levels are usually associated with ageing and inflammatory conditions. Bariatric surgery resulted in extensive alterations of the IgG glycome that accompanied progressive weight loss during one-year follow-up. We observed a significant increase in digalactosylated and sialylated glycans, and a substantial decrease in agalactosylated and core fucosylated IgG glycans. In general, this IgG glycan profile is associated with a younger biological age and reflects an enhanced anti-inflammatory IgG potential. Loss of BMI over a 20 year period in the TwinsUK cohort validated a weight loss-associated agalactosylation decrease and an increase in digalactosylation. Conclusions: Altogether, these findings highlight that weight loss substantially affects IgG N-glycosylation, resulting in reduced biological and immune age. GRAPHICAL HIGHLIGHTS: Obesity is associated to inflammation-related agalactosylated and bisected IgG glycoforms IgG galactosylation and sialylation increase after bariatric surgery-induced weight loss Progressive decrease of BMI is associated to increased IgG galactosylation, implying a reduction of biological age

5 August 2015 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
MMM. Musumeci
M. Musumeci
APAndrea Palermo
Andrea Palermo
LDL. D’oNofrio
L. D’oNofrio
Gianluca VadalàGianluca Vadalà
Gianluca Vadalà
VGV. Greto
V. Greto
SMS. Manfrini
S. Manfrini